Skip to main content
Erschienen in: Clinical and Translational Oncology 4/2020

15.06.2019 | Research Article

ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling

verfasst von: X. Xuan, J. Zhou, Z. Tian, Y. Lin, J. Song, Z. Ruan, B. Ni, H. Zhao, W. Yang

Erschienen in: Clinical and Translational Oncology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Type 3 innate lymphocytes (ILC3s) are reported to be involved in lung cancer, possibly by producing interleukin-22 (IL-22). However, whether ILC3s and their secreted IL-22 molecules contribute to the pathogenesis of pancreatic cancer (PC) remains unclear. To this end, in this study, we investigated the effects and possible mechanisms of ILC3s on PC pathogenesis.

Method

The IL-22 and IL-2i2R levels and the ILC3s’ frequency in cancer tissues from PC patients and in peripheral blood from PC patients and healthy controls were analyzed by flow cytometry, immunochemistry, or immunofluorescence. The effects of IL-22-induced AKT signaling on the proliferation, invasion, and migration of PC cells were examined by co-culturing PC cell lines with ILC3s isolated from PC tissues, with or without the addition of neutralizing IL-22 antibody, IL-22R antibody or AKT inhibitor.

Results

Our results showed that IL-22 and ILC3s were significantly upregulated in the PBMCs and cancer tissues of PC patients, and the IL-22R level was increased in PC cells. The increased frequency of ILC3s was positively correlated with the clinical features of PC patients. Co-culture experiments indicated that ILC3s promoted the proliferation, invasion, and migration of PC cell lines by secreting IL-22 to activate AKT signaling because IL-22/IL-22R or AKT blockage markedly counteracted such effects on PC cells.

Conclusion

Our data demonstrated that ILC3s may promote PC pathogenesis through IL-22/IL-22R-AKT signaling, suggesting a potential intervention target for PC treatment in the future.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Karamitopoulou E, Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br J Cancer 2019. Karamitopoulou E, Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br J Cancer 2019.
2.
Zurück zum Zitat Nitsche C, et al. Environmental risk factors for chronic pancreatitis and pancreatic cancer. Dig Dis. 2011;29(2):235–42.CrossRef Nitsche C, et al. Environmental risk factors for chronic pancreatitis and pancreatic cancer. Dig Dis. 2011;29(2):235–42.CrossRef
3.
Zurück zum Zitat Dalgleish AG, O'Byrne K. Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat Res. 2006;130:1–38.CrossRef Dalgleish AG, O'Byrne K. Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat Res. 2006;130:1–38.CrossRef
4.
Zurück zum Zitat Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117(5):1175–83.CrossRef Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117(5):1175–83.CrossRef
5.
Zurück zum Zitat Carrega P, et al. NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat Commun. 2015;6:8280.CrossRef Carrega P, et al. NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat Commun. 2015;6:8280.CrossRef
6.
Zurück zum Zitat Spits H, Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol. 2012;30:647–75.CrossRef Spits H, Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol. 2012;30:647–75.CrossRef
7.
Zurück zum Zitat Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517(7534):293–301.CrossRef Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517(7534):293–301.CrossRef
8.
Zurück zum Zitat Spits H, et al. Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13(2):145–9.CrossRef Spits H, et al. Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13(2):145–9.CrossRef
9.
Zurück zum Zitat Eberl G. Development and evolution of RORgammat+ cells in a microbe's world. Immunol Rev. 2012;245(1):177–88.CrossRef Eberl G. Development and evolution of RORgammat+ cells in a microbe's world. Immunol Rev. 2012;245(1):177–88.CrossRef
10.
Zurück zum Zitat Chevalier MF, et al. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest. 2017;127(8):2916–29.CrossRef Chevalier MF, et al. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest. 2017;127(8):2916–29.CrossRef
11.
Zurück zum Zitat Xuan X, et al. Diverse effects of interleukin-22 on pancreatic diseases. Pancreatology. 2018;18(3):231–7.CrossRef Xuan X, et al. Diverse effects of interleukin-22 on pancreatic diseases. Pancreatology. 2018;18(3):231–7.CrossRef
12.
Zurück zum Zitat Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol. 2011;12(5):383–90.CrossRef Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol. 2011;12(5):383–90.CrossRef
13.
Zurück zum Zitat Curd LM, Favors SE, Gregg RK. Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells. Clin Exp Immunol. 2012;168(2):192–9.CrossRef Curd LM, Favors SE, Gregg RK. Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells. Clin Exp Immunol. 2012;168(2):192–9.CrossRef
14.
Zurück zum Zitat Lin H, et al. Knockdown of OCT4 suppresses the growth and invasion of pancreatic cancer cells through inhibition of the AKT pathway. Mol Med Rep. 2014;10(3):1335–422.CrossRef Lin H, et al. Knockdown of OCT4 suppresses the growth and invasion of pancreatic cancer cells through inhibition of the AKT pathway. Mol Med Rep. 2014;10(3):1335–422.CrossRef
15.
Zurück zum Zitat Van Maele L, et al. Activation of Type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during Streptococcus pneumoniae infection. J Infect Dis. 2014;210(3):493–503.CrossRef Van Maele L, et al. Activation of Type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during Streptococcus pneumoniae infection. J Infect Dis. 2014;210(3):493–503.CrossRef
16.
Zurück zum Zitat Montaldo E, Juelke K, Romagnani C. Group 3 innate lymphoid cells (ILC3s): origin, differentiation, and plasticity in humans and mice. Eur J Immunol. 2015;45(8):2171–82.CrossRef Montaldo E, Juelke K, Romagnani C. Group 3 innate lymphoid cells (ILC3s): origin, differentiation, and plasticity in humans and mice. Eur J Immunol. 2015;45(8):2171–82.CrossRef
17.
Zurück zum Zitat Niccolai E, et al. Intra-tumoral IFN-gamma-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. Clin Sci (Lond). 2016;130(4):247–58.CrossRef Niccolai E, et al. Intra-tumoral IFN-gamma-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. Clin Sci (Lond). 2016;130(4):247–58.CrossRef
18.
Zurück zum Zitat Sautes-Fridman C, et al. Tumor microenvironment is multifaceted. Cancer Metastasis Rev. 2011;30(1):13–25.CrossRef Sautes-Fridman C, et al. Tumor microenvironment is multifaceted. Cancer Metastasis Rev. 2011;30(1):13–25.CrossRef
19.
Zurück zum Zitat Wolk K, et al. IL-22 increases the innate immunity of tissues. Immunity. 2004;21(2):241–54.CrossRef Wolk K, et al. IL-22 increases the innate immunity of tissues. Immunity. 2004;21(2):241–54.CrossRef
20.
Zurück zum Zitat Lo YH, et al. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci. 2010;58(3):225–7.CrossRef Lo YH, et al. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci. 2010;58(3):225–7.CrossRef
21.
Zurück zum Zitat Zhang L, et al. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J Clin Immunol. 2011;31(4):606–14.CrossRef Zhang L, et al. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J Clin Immunol. 2011;31(4):606–14.CrossRef
22.
Zurück zum Zitat Saalim M, et al. IL-22: a promising candidate to inhibit viral-induced liver disease progression and hepatocellular carcinoma. Tumour Biol. 2016;37(1):105–14.CrossRef Saalim M, et al. IL-22: a promising candidate to inhibit viral-induced liver disease progression and hepatocellular carcinoma. Tumour Biol. 2016;37(1):105–14.CrossRef
23.
Zurück zum Zitat Zhuang Y, et al. Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol Immunother. 2012;61(11):1965–75.CrossRef Zhuang Y, et al. Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol Immunother. 2012;61(11):1965–75.CrossRef
24.
Zurück zum Zitat Kinnebrew MA, et al. Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity. 2012;36(2):276–87.CrossRef Kinnebrew MA, et al. Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity. 2012;36(2):276–87.CrossRef
25.
Zurück zum Zitat Van Maele L, et al. TLR5 signaling stimulates the innate production of IL-17 and IL-22 by CD3(neg)CD127+ immune cells in spleen and mucosa. J Immunol. 2010;185(2):1177–85.CrossRef Van Maele L, et al. TLR5 signaling stimulates the innate production of IL-17 and IL-22 by CD3(neg)CD127+ immune cells in spleen and mucosa. J Immunol. 2010;185(2):1177–85.CrossRef
26.
Zurück zum Zitat Satpathy AT, et al. Notch2-dependent classical dendritic cells orchestrate intestinal immunity to attaching-and-effacing bacterial pathogens. Nat Immunol. 2013;14(9):937–48.CrossRef Satpathy AT, et al. Notch2-dependent classical dendritic cells orchestrate intestinal immunity to attaching-and-effacing bacterial pathogens. Nat Immunol. 2013;14(9):937–48.CrossRef
27.
Zurück zum Zitat Monticelli LA, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol. 2011;12(11):1045–54.CrossRef Monticelli LA, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol. 2011;12(11):1045–54.CrossRef
28.
Zurück zum Zitat Taube C, et al. IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease. PLoS ONE. 2011;6(7):e21799.CrossRef Taube C, et al. IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease. PLoS ONE. 2011;6(7):e21799.CrossRef
29.
Zurück zum Zitat Goto Y, et al. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science. 2014;345(6202):1254009.CrossRef Goto Y, et al. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science. 2014;345(6202):1254009.CrossRef
30.
Zurück zum Zitat Vivier E, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–10.CrossRef Vivier E, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–10.CrossRef
31.
Zurück zum Zitat Neill DR, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367–70.CrossRef Neill DR, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367–70.CrossRef
32.
Zurück zum Zitat Kirchberger S, et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med. 2013;210(5):917–31.CrossRef Kirchberger S, et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med. 2013;210(5):917–31.CrossRef
33.
Zurück zum Zitat Zhao D, et al. Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. Int J Cancer. 2015;136(11):2556–655.CrossRef Zhao D, et al. Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. Int J Cancer. 2015;136(11):2556–655.CrossRef
Metadaten
Titel
ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling
verfasst von
X. Xuan
J. Zhou
Z. Tian
Y. Lin
J. Song
Z. Ruan
B. Ni
H. Zhao
W. Yang
Publikationsdatum
15.06.2019
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 4/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02160-5

Weitere Artikel der Ausgabe 4/2020

Clinical and Translational Oncology 4/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.